A Case Report of a Severely Immunocompromised Patient with Clinically Amyopathic Dermatomyositis-related ILD: Is CMV-prevention Indicated?

Bernhardt Ae, Leavis Hl, Verduyn Luynel Fm, Mohamed Hoesein Faa, M. Voortman, Kwakkel-van Erp Jm
{"title":"A Case Report of a Severely Immunocompromised Patient with Clinically Amyopathic Dermatomyositis-related ILD: Is CMV-prevention Indicated?","authors":"Bernhardt Ae, Leavis Hl, Verduyn Luynel Fm, Mohamed Hoesein Faa, M. Voortman, Kwakkel-van Erp Jm","doi":"10.4172/2161-105X.1000480","DOIUrl":null,"url":null,"abstract":"We herein report a case of a 59-year old female with rapidly progressive interstitial lung disease due to antiMDA-5 positive clinically amyopathic dermatomyositis. Despite initial response to a combination high dose immunosuppressive treatment, her respiratory condition deteriorated and she was screened for urgent lung transplantation. During screening an active CMV-infection was revealed, which made her ineligible for the procedure. Unfortunately, despite CMV treatment, the patient died due to her pulmonary condition. Since more aggressive immunosuppressive regimens increase risk of viral reactivation, and after reviewing the literature, we debated if in analogue with solid organ transplantation, CMV prevention or monitoring should be applied to optimize clinical outcome. *Corresponding author: Johanna Kwakkel-van Erp, Department of Pulmonology, University Hospital Antwerpen (UZA), Edegem, Belgium, Tel: +32468040187, Fax: +3238214447; E-mail: Johanna.Kwakkel-vanErp@uza.be Received November 08, 2018; Accepted November 14, 2018; Published November 21, 2018 Citation: Bernhard AE, Leavis HL, Verduyn Luynel FM, Mohamed Hoesein FAA, Voortman M, et al. (2018) A Case Report of a Severely Immunocompromised Patient with Clinically Amyopathic Dermatomyositis-related ILD: Is CMV-prevention Indicated?. J Pulm Respir Med 8: 480. doi: 10.4172/2161-105X.1000480 Copyright: ©2018 Bernhard AE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","PeriodicalId":90449,"journal":{"name":"Austin journal of pulmonary and respiratory medicine","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin journal of pulmonary and respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-105X.1000480","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We herein report a case of a 59-year old female with rapidly progressive interstitial lung disease due to antiMDA-5 positive clinically amyopathic dermatomyositis. Despite initial response to a combination high dose immunosuppressive treatment, her respiratory condition deteriorated and she was screened for urgent lung transplantation. During screening an active CMV-infection was revealed, which made her ineligible for the procedure. Unfortunately, despite CMV treatment, the patient died due to her pulmonary condition. Since more aggressive immunosuppressive regimens increase risk of viral reactivation, and after reviewing the literature, we debated if in analogue with solid organ transplantation, CMV prevention or monitoring should be applied to optimize clinical outcome. *Corresponding author: Johanna Kwakkel-van Erp, Department of Pulmonology, University Hospital Antwerpen (UZA), Edegem, Belgium, Tel: +32468040187, Fax: +3238214447; E-mail: Johanna.Kwakkel-vanErp@uza.be Received November 08, 2018; Accepted November 14, 2018; Published November 21, 2018 Citation: Bernhard AE, Leavis HL, Verduyn Luynel FM, Mohamed Hoesein FAA, Voortman M, et al. (2018) A Case Report of a Severely Immunocompromised Patient with Clinically Amyopathic Dermatomyositis-related ILD: Is CMV-prevention Indicated?. J Pulm Respir Med 8: 480. doi: 10.4172/2161-105X.1000480 Copyright: ©2018 Bernhard AE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
1例严重免疫功能低下的临床淀粉样皮肌炎相关ILD患者:是否需要cmv预防?
我们在此报告一例59岁女性因抗肽-5阳性临床淀粉性皮肌炎而迅速进展的间质性肺病。尽管对联合高剂量免疫抑制治疗有初步反应,但她的呼吸状况恶化,并对她进行了紧急肺移植筛查。在筛查过程中发现了活跃的巨细胞病毒感染,这使她不符合手术条件。不幸的是,尽管巨细胞病毒治疗,患者死于肺部疾病。由于更积极的免疫抑制方案会增加病毒再激活的风险,在回顾文献后,我们讨论是否与实体器官移植类似,CMV预防或监测应该应用于优化临床结果。*通讯作者:Johanna Kwakkel-van Erp,比利时安特卫普大学医院肺内科,电话:+32468040187,传真:+3238214447;邮箱:Johanna.Kwakkel-vanErp@uza.be 2018年11月08日收稿;2018年11月14日录用;引用本文:Bernhard AE, Leavis HL, Verduyn Luynel FM, Mohamed Hoesein FAA, Voortman M等。(2018)1例严重免疫功能低下的临床淀粉样皮肌炎相关ILD患者:是否需要cmv预防?[J]中华肺科杂志,8:48。2161 - 105 - x.1000480 doi: 10.4172 /版权所有:©2018 Bernhard AE, et al。这是一篇根据知识共享署名许可协议发布的开放获取文章,该协议允许在任何媒体上不受限制地使用、分发和复制,前提是要注明原作者和来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信